{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:02:13Z","timestamp":1750478533147,"version":"3.41.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-070","2022-PUMCH-B-071"],"award-info":[{"award-number":["2022-PUMCH-B-070","2022-PUMCH-B-071"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS, 2024-I2M-C&T-B-034"],"award-info":[{"award-number":["CIFMS, 2024-I2M-C&T-B-034"]}]},{"name":"Peking Union Medical College Hospital Talent Cultivation Program","award":["UBJ10707"],"award-info":[{"award-number":["UBJ10707"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01262-2","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T08:16:20Z","timestamp":1750407380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced splenic uptake of [68Ga]Ga-Pentixafor following first-line chemotherapy is associated with poor prognosis in patients with newly diagnosed multiple myeloma"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-0767","authenticated-orcid":false,"given":"Qingqing","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-1136","authenticated-orcid":false,"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"1262_CR1","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"1262_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41375-018-0271-1","volume":"33","author":"S Sidana","year":"2019","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. 2019;33:730\u20138. https:\/\/doi.org\/10.1038\/s41375-018-0271-1","journal-title":"Leukemia"},{"key":"1262_CR3","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/jco.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research Council myeloma IX study. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31:2540\u20137. https:\/\/doi.org\/10.1200\/jco.2012.46.2119","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1262_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2013.217","volume":"28","author":"N Puig","year":"2014","unstructured":"Puig N, Sarasquete ME, Balanzategui A, Mart\u00ednez J, Paiva B, Garc\u00eda H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28:391\u20137. https:\/\/doi.org\/10.1038\/leu.2013.217","journal-title":"Leukemia"},{"key":"1262_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/jco.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33:657\u201364. https:\/\/doi.org\/10.1200\/jco.2014.57.9961","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1262_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477\u201387. https:\/\/doi.org\/10.15252\/emmm.201404698","journal-title":"EMBO Mol Med"},{"key":"1262_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kortum KM, Herrmann K, et al. [(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values. Theranostics. 2017;7:205\u201312. https:\/\/doi.org\/10.7150\/thno.16576","journal-title":"Theranostics"},{"key":"1262_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/RLU.0000000000002067","volume":"43","author":"Q Pan","year":"2018","unstructured":"Pan Q, Luo Y, Cao X, Ma Y, Li F. Multiple myeloma presenting as a superscan on 68Ga-Pentixafor PET\/CT. Clin Nucl Med. 2018;43:462\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000002067","journal-title":"Clin Nucl Med"},{"key":"1262_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47:537\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04605-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1262_CR10","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.75847","volume":"12","author":"S Kraus","year":"2022","unstructured":"Kraus S, Klassen P, Kircher M, Dierks A, Habringer S, G\u00e4ble A, et al. Reduced Splenic uptake on (68)Ga-Pentixafor-PET\/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics. 2022;12:5986\u201394. https:\/\/doi.org\/10.7150\/thno.75847","journal-title":"Theranostics"},{"key":"1262_CR11","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/jco.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320. https:\/\/doi.org\/10.1200\/jco.2005.04.242","journal-title":"J Clin Oncol"},{"key":"1262_CR12","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139. https:\/\/doi.org\/10.1200\/jco.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"1262_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13550-021-00822-6","volume":"11","author":"R Lewis","year":"2021","unstructured":"Lewis R, Habringer S, Kircher M, Hefter M, Peuker CA, Werner R, et al. Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res. 2021;11:77. https:\/\/doi.org\/10.1186\/s13550-021-00822-6","journal-title":"EJNMMI Res"},{"key":"1262_CR14","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/jco.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-Computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35:2911\u20138. https:\/\/doi.org\/10.1200\/jco.2017.72.2975","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1262_CR15","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.Ccr-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, et al. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21:4384\u201390. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0396","journal-title":"Clin Cancer Res"},{"key":"1262_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","volume":"21","author":"F Patriarca","year":"2015","unstructured":"Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:1068\u201373. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.001","journal-title":"Biol Blood Marrow Transpl"},{"key":"1262_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1600-0609.2010.01575.x","volume":"86","author":"BM Elliott","year":"2011","unstructured":"Elliott BM, Peti S, Osman K, Scigliano E, Lee D, Isola L, et al. Combining FDG-PET\/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol. 2011;86:289\u201398. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01575.x","journal-title":"Eur J Haematol"},{"key":"1262_CR18","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr., van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376. https:\/\/doi.org\/10.1182\/blood-2009-03-213280","journal-title":"Blood"},{"key":"1262_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/RLU.0000000000003760","volume":"46","author":"Q Pan","year":"2021","unstructured":"Pan Q, Cao X, Luo Y, Li J, Li F. Chemokine receptor 4-Targeted 68Ga-Pentixafor PET\/CT in response assessment of Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET\/CT. Clin Nucl Med. 2021;46:732\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000003760","journal-title":"Clin Nucl Med"},{"key":"1262_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-021-00852-0","volume":"11","author":"Q Pan","year":"2021","unstructured":"Pan Q, Cao X, Luo Y, Li J, Li F. Semi-quantitative measurements of chemokine receptor 4-targeted (68)Ga-pentixafor PET\/CT in response assessment of Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma. EJNMMI Res. 2021;11:110. https:\/\/doi.org\/10.1186\/s13550-021-00852-0","journal-title":"EJNMMI Res"},{"key":"1262_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/rlu.0000000000002258","volume":"43","author":"W Cytawa","year":"2018","unstructured":"Cytawa W, Kircher S, Schirbel A, Shirai T, Fukushima K, Buck AK, et al. Chemokine receptor 4 expression in primary Sjogren\u2019s syndrome. Clin Nucl Med. 2018;43:835\u20136. https:\/\/doi.org\/10.1097\/rlu.0000000000002258","journal-title":"Clin Nucl Med"},{"key":"1262_CR22","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2967\/jnumed.117.193037","volume":"58","author":"T Derlin","year":"2017","unstructured":"Derlin T, Gueler F, Brasen JH, Schmitz J, Hartung D, Herrmann TR, et al. Integrating MRI and chemokine receptor CXCR4-Targeted PET for detection of leukocyte infiltration in complicated urinary tract infections after kidney transplantation. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2017;58:1831\u20137. https:\/\/doi.org\/10.2967\/jnumed.117.193037","journal-title":"Soc Nuclear Med"},{"key":"1262_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/RLU.0000000000003004","volume":"45","author":"Q Pan","year":"2020","unstructured":"Pan Q, Luo Y, Cao X, Li J, Li F. Pulmonary cryptococcosis accidentally detected by 68Ga-Pentixafor PET\/CT in a patient with multiple myeloma. Clin Nucl Med. 2020;45:423\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000003004","journal-title":"Clin Nucl Med"},{"key":"1262_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1084\/jem.20041185","volume":"200","author":"Y Nie","year":"2004","unstructured":"Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med. 2004;200:1145\u201356. https:\/\/doi.org\/10.1084\/jem.20041185","journal-title":"J Exp Med"},{"key":"1262_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-immunol-041015-055649","volume":"34","author":"O Schulz","year":"2016","unstructured":"Schulz O, Hammerschmidt SI, Moschovakis GL, F\u00f6rster R. Chemokines and chemokine receptors in lymphoid tissue dynamics. Annu Rev Immunol. 2016;34:203\u201342. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055649","journal-title":"Annu Rev Immunol"},{"key":"1262_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4329\/wjr.v5.i3.68","volume":"5","author":"AC Morani","year":"2013","unstructured":"Morani AC, Elsayes KM, Liu PS, Weadock WJ, Szklaruk J, Dillman JR, et al. Abdominal applications of diffusion-weighted magnetic resonance imaging: where do we stand. World J Radiol. 2013;5:68\u201380. https:\/\/doi.org\/10.4329\/wjr.v5.i3.68","journal-title":"World J Radiol"},{"key":"1262_CR27","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.7150\/thno.33289","volume":"9","author":"L Rasche","year":"2019","unstructured":"Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, et al. Lack of spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: A link to extramedullary hematopoiesis?? Theranostics. 2019;9:4756\u201363. https:\/\/doi.org\/10.7150\/thno.33289","journal-title":"Theranostics"},{"key":"1262_CR28","doi-asserted-by":"publisher","first-page":"23978","DOI":"10.1038\/s41598-021-03496-1","volume":"11","author":"T Terao","year":"2021","unstructured":"Terao T, Machida Y, Tateishi U, Tsushima T, Narita K, Ikeda D, et al. Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma. Sci Rep. 2021;11:23978. https:\/\/doi.org\/10.1038\/s41598-021-03496-1","journal-title":"Sci Rep"},{"key":"1262_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective Cancer immunotherapy. Cell. 2017;168:487\u2013e50215. https:\/\/doi.org\/10.1016\/j.cell.2016.12.022","journal-title":"Cell"},{"key":"1262_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","volume":"2","author":"S Ugel","year":"2012","unstructured":"Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012;2:628\u201339. https:\/\/doi.org\/10.1016\/j.celrep.2012.08.006","journal-title":"Cell Rep"},{"key":"1262_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05045.x","volume":"126","author":"GP Mead","year":"2004","unstructured":"Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126:348\u201354. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05045.x","journal-title":"Br J Haematol"},{"key":"1262_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.12376","volume":"93","author":"CT Hansen","year":"2014","unstructured":"Hansen CT, Pedersen PT, Nielsen LC, Abildgaard N. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol. 2014;93:407\u201313. https:\/\/doi.org\/10.1111\/ejh.12376","journal-title":"Eur J Haematol"},{"key":"1262_CR33","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1200\/jco.2008.21.1060","volume":"27","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99\u2009\u2013\u200902 and 99\u2009\u2013\u200904. Trials J Clin Oncology: Official J Am Soc Clin Oncol. 2009;27:5720\u20136. https:\/\/doi.org\/10.1200\/jco.2008.21.1060","journal-title":"Trials J Clin Oncology: Official J Am Soc Clin Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01262-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T08:16:21Z","timestamp":1750407381000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01262-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01262-2","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We performed this study in compliance with the 1964 Helsinki Declaration and its later amendments and federal laws in China. The study was approved by the Institutional Review Board in Peking Union Medical College Hospital and the First Affiliated Hospital, Fujian Medical University (ZS-1810, [2019]293) and registered at ClinicalTrials (NCT 03436342, 04504526).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed written informed consent for the use of their data in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}